Table 3.
Compliance with and impact of a comprehensive care bundle on candidemia
| Intervention group (n = 56) | Control group (n = 53) | p value* | |
|---|---|---|---|
| All bundle elements successfully completed | 27 (48.2) | 43 (81.1) | 0.01 |
| Early adequate source control of infection | 37 (82.2) | 41 (97.6) | 0.03 |
| Early adequate antifungal therapy | 47 (83.9) | 51 (96.2) | 0.05 |
| At least one complication detected | 10 (20.8) | 19 (38.0) | 0.08 |
| Blood cultures every 48 h until negative | 50 (89.3) | 51 (96.2) | 0.27 |
| Persistent candidemia | 15/51 (29.4) | 8/51 (16.0) | 0.15 |
| Ophthalmologic examination performed | 47 (83.9) | 49 (92.5) | 0.23 |
| Ocular candidiasis | 5/47 (10.6) | 10/49 (20.4) | 0.26 |
| Echocardiograms performed | 47 (83.9) | 48 (90.6) | 0.34 |
| Trans-thoracic | 22 (46.8) | 18 (37.5) | |
| Trans-esophageal | 25 (53.2) | 30 (62.5) | |
| Infective endocarditis | 0/46 (0) | 2/48 (4.2) | 0.49 |
| Other complications | |||
| Thrombophlebitis | 4/9 (44.4) | 5/11 (45.5) | 1 |
| Spread to other organs | 1/56 (1.8) | 7/53 (13.2) | 0.03 |
| Appropriate duration of therapy | 45 (80.4) | 51 (96.2) | 0.01 |
*P values < 0.05 are shown in bold